Ronald Hoffman, MD

Ronald Hoffman, MD

DirectorMyeloproliferative Disorders Research Program, Tisch Cancer Institute, Mount Sinai

long bio placeholder

Related

Rusfertide Reduces Phlebotomy Need for Polycythemia Vera Patients
Myeloproliferative Neoplasms

Rusfertide Reduces Phlebotomy Need for Polycythemia Vera Patients

Ronald Hoffman, MD of Tisch Cancer Institute, Mount Sinai, shares encouraging results of clinical trials of Rusfertide in polycythemia vera patients who are phlebotomy dependent. Rusfertide is shown to maintain target hematocrit levels and reduce or eliminate the need for phlebotomy in phlebotomy-dependent patients.

Rusfertide Reduces Phlebotomy Need for Polycythemia Vera Patients
Myeloproliferative Neoplasms

Rusfertide Reduces Phlebotomy Need for Polycythemia Vera Patients

Ronald Hoffman, MD of Tisch Cancer Institute, Mount Sinai, shares encouraging results of clinical trials of Rusfertide in polycythemia vera patients who are phlebotomy dependent. Rusfertide is shown to maintain target hematocrit levels and reduce or eliminate the need for phlebotomy in phlebotomy-dependent patients.